Akums receives DCGI approval for triple combination diabetes treatment

Akums Drugs and Pharmaceuticals has secured approval from Drugs Controller General of India for its ground-breaking triple combination diabetes treatment. Sitagliptin 100, pioglitazone 15 and metformin 1000/500 comes as a more advanced treatment for diabetes, with much more efficacy and precision than monotherapy drugs that are currently in the market.

Sitagliptin 100, pioglitazone 15 and metformin 1000/500 is specifically formulated for the treatment of diabetes and offers a number of pharmacological advantages.

The combination contains three distinctly active formulations such as metformin, a glucose-lowering agent often prescribed as a first-line therapy for type-2 diabetes (T2D).

"We have carefully studied the pharmacological properties of these formulations and with sitagliptin 100, pioglitazone 15 and metformin 1000/500, we found the right blend for our triple-active combination. This is going to better serve anti-diabetic patients who require better treatment without necessarily swallowing multiple drugs. The approval is a boost because it shows that we followed all laid down procedures, and the drug is fit for use by patients who need relief from the impacts of not just type-2 diabetes, Patient convenience and dosage compliance " said Sanjeev Jain, joint managing director, Akums Drugs & Pharmaceuticals.

The bi-layered combination was formulated following well-researched processes and operations, as well as adherence to pharmacological guidelines. Speaking on the approval, Sandeep Jain, jt. managing director, Akums Drugs & Pharmaceuticals, noted that the renoprotective effects of drugs like metformin coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome, and the stability of sitagliptin, make an effective solution for diabetes.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!